Mouse serum exposure to DHM depended on administration route and sex. At 50 mg/kg, intraperitoneal dosing produced higher serum AUC than oral gavage; these exposure measurements do not establish human efficacy. [2]
In a small male Wistar rat experiment, oral DHM 10 mg/kg did not significantly lower blood ethanol or acetaldehyde after the first ethanol challenge. Blood concentrations were higher at 60 minutes after next-day ethanol-only rechallenge in animals previously given DHM. [3]
Route and sex dependence of serum DHM exposure
Animal study · Eight-week-old male and female C57BL/6J mice [2]
At the same nominal dose, serum exposure was higher after intraperitoneal administration than oral gavage. Values below follow Table 1 and Results §2.2; abstract fold-change sex labels are inconsistent.
Conditions shared by the study groups
- Frequency
- Single administration
- Treatment course
- Serum sampling through 24 h
- Vehicle
- 0.9% saline with 10% DMSO
- Female Oral gavage
- Model: Female C57BL/6J mice
- Route: Oral gavage
- Reported limits: No IV comparator; absolute bioavailability not determined.
- Male Oral gavage
- Model: Male C57BL/6J mice
- Route: Oral gavage
- Reported limits: No IV comparator; absolute bioavailability not determined.
- Female Intraperitoneal injection
- Model: Female C57BL/6J mice
- Route: Intraperitoneal injection
- Reported limits: No IV comparator; absolute bioavailability not determined.
- Male Intraperitoneal injection
- Model: Male C57BL/6J mice
- Route: Intraperitoneal injection
- Reported limits: No IV comparator; absolute bioavailability not determined.
Methods and source locations
Compound reported in the paper: Dihydromyricetin; Compound label in the paper: DHM
Serum exposure in mice; no human dose or free brain concentration inference.
Table 1 serum rows and Figure 2; Results §2.2; Methods §§4.1–4.5 and 4.9
Serum DHM exposure, AUC0→24: UPLC-QqQ/MS; DHM standard retention time/MRM and calibration curve; isoquercetin internal standard; n = 3–4 per sex/time point; AUC by noncompartmental trapezoidal integration (§4.9) — Table 1 serum AUC row; Results §2.2; Methods §§4.2–4.5 and 4.9
Female Oral gavage · Table 1 serum AUC row; Methods §§4.1–4.5
Male Oral gavage · Table 1 serum AUC row; Methods §§4.1–4.5
Female Intraperitoneal injection · Table 1 serum AUC row; Methods §§4.1–4.5
Male Intraperitoneal injection · Table 1 serum AUC row; Methods §§4.1–4.5
Oral DHM did not accelerate ethanol disappearance in a rat experiment
Animal study · Male Wistar rats, 300–400 g [3]
The first challenge showed no significant decrease in blood ethanol or acetaldehyde with DHM. On next-day ethanol rechallenge, blood ethanol was higher at 60 min in rats previously given DHM. Small animal groups limit precision.
Conditions shared by the study groups
- Route
- Gastric gavage
- Frequency
- One DHM coadministration on day 1
- Treatment course
- Blood sampling 5–60 min on day 1 and after ethanol-only rechallenge 24 h later
- DHM plus ethanol versus ethanol alone, with rechallenge
- Model: Male Wistar rats
- Reported limits: Ethanol administered volume/g/kg dose and separate DHM solvent not specified; n falls from 4 to 2 per group on rechallenge.
Methods and source locations
Compound reported in the paper: Dihydromyricetin; Compound label in the paper: DHM
Results apply to the reported DHM preparation; exact stereochemical/lot equivalence to this SKU is unverified.
Methods: reagents, Animals, Alcohol metabolism in vivo, Statistics; Results: Effect of DHM on metabolism of ethanol in vivo; Figure 4A–D and caption
Blood ethanol and acetaldehyde after first exposure and next-day rechallenge: Headspace GC in triplicate; n = 4 rats/group first day and n = 2/group rechallenge; technical triplicates do not increase animal n; caption reports mean ± SD. — Figure 4A–D; Alcohol metabolism in vivo; corresponding Results
DHM plus ethanol versus ethanol alone, with rechallenge · Alcohol metabolism in vivo; Figure 4A–D and caption; corresponding Results
